vialaudit
TIRZEPATIDE·CALIFORNIA·LAST CHECKED 1 NOV 2026

Is Tirzepatide legal in California?

CAVEATS APPLY

California's pharmacy rules, adopted 17 Jun 2025, treat any compounded drug with the same active ingredient as a commercial product as 'essentially a copy' unless the pharmacist documents a clinically significant difference for the patient. That is stricter than FDA's test, which also looks at strength and route. Federally: Yes, as a prescription drug: FDA has approved it (Mounjaro, Zepbound). A vial sold as a 'research peptide' is not the approved product, and selling it for human use breaks federal drug law. Pharmacies may compound it only when the product is not a copy of the approved drug.

CATEGORY · FDA APPROVED

Full status breakdown

FEDERAL · STATE · SPORT-BODY

Federal status

FDA approval
approved as drug · brand: Mounjaro, Zepbound · NDA 215866 (Mounjaro); NDA 217806 (Zepbound) · approved May 13, 2022
Indications: T2DM; chronic weight management; OSA
DEA scheduling
not scheduled
503A compounding
FDA interim category: Component of an FDA-approved drug
503A Bulks List: not on list
Component of an approved drug, so a 503A pharmacy may compound it only when the result is not 'essentially a copy' of Mounjaro or Zepbound. FDA's shortage-period discretion ended 18 Feb 2025 (503A) and 19 Mar 2025 (503B). FDA proposed on 1 May 2026 to exclude tirzepatide from the 503B clinical-need list; the comment period was extended and closed 30 Jul 2026, and no final notice was in the Federal Register as of 12 Oct 2026.
FDA Warning Letters
  • Dec 10, 2024 — Summit Research Peptides (cited: tirzepatide, retatrutide) · LETTER ↗
  • Sep 9, 2025 — Hims & Hers Health Inc dba Hers (cited: tirzepatide, semaglutide) · LETTER ↗
  • Feb 20, 2026 — Better Health Labs Inc dba Measured (cited: tirzepatide) · LETTER ↗
  • Mar 31, 2026 — Gram Peptides (cited: tirzepatide, retatrutide) · LETTER ↗
Shortage status
not currently on shortage list
Historical shortage window: Apr 1, 2024 → Dec 19, 2024
Sale framing
Research-use-only posture: RUO label does not legalize sale to consumers when site evidence shows human-use intent. FDA has issued 30+ warning letters across 2024-2026.
Personal possession: Federally unscheduled; possession by an end-user is not a federal criminal offense, but unapproved compounded/illicit tirzepatide carries FDA enforcement risk on the seller side plus state pharmacy law risk.

California — state-specific

compounding restriction · California

California's pharmacy rules, adopted 17 Jun 2025, treat any compounded drug with the same active ingredient as a commercial product as 'essentially a copy' unless the pharmacist documents a clinically significant difference for the patient. That is stricter than FDA's test, which also looks at strength and route.

Sport-body status

WADA 2026
not prohibited
GLP-1 receptor agonists are not on the 2026 or the 2027 Prohibited List. WADA's 2027 Monitoring Program names tirzepatide, which tracks use but does not ban it.
USADA
not banned
NCAA
unknown

What we couldn’t verify

Also known as

6 ALIASES

Tirzepatide is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):

  • LY3298176
  • Mounjaro
  • Zepbound
  • GIP/GLP-1 dual agonist
  • Tirz
  • Tirze

Related

FOLLOW-ONS

Tirzepatide: US status, sources and what changed

Other states with a rule that names Tirzepatide: Mississippi, Connecticut, Alabama, Ohio, Indiana. Everywhere else, federal law applies.

THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH